Comment on Nachum et al. Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. Diabetes Care 2017;40:332–337
Abstract
Given the increasing popularity of oral agents, we commend Nachum et al. (1) on their randomized controlled trial examining metformin or glyburide as a first-line agent to treat gestational diabetes mellitus (GDM) and adding or switching to the alternate agent for adverse events or failures. However, we question whether the study design and conclusions can be generalized to many GDM populations.
First, a GDM diagnosis was made at <24 weeks in 27 of 104 patients, suggesting impaired glucose tolerance predating the pregnancy in ∼25%. An early GDM diagnosis increased the risk of failing glyburide by about eightfold in our series (2). A recent cohort also demonstrated that pregnancies with GDM diagnosed …
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 27 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.